Psyrex CNS Bio-Tech Ltd.
TTASE:PSRX58.40
ILA
-3.60
(-5.81%)
Psyrex CNS Bio-Tech Ltd.
TASE:PSRX
(Tel Aviv Stock Exchange)
Recent
price
58.40
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- PsyRx CNS Bio-Tech Ltd is a biotechnology company focused on the development of next-generation antidepressant therapies by combining low-dose ibogaine with established selective serotonin reuptake inhibitors (SSRIs) to enhance neuroplasticity and improve psychiatric outcomes. The company advances novel combination drug therapies designed to accelerate onset of action, improve response in difficult-to-treat populations, and reduce side effects while preserving patient daily functioning. PsyRx manufactures and supplies GMP-standard active pharmaceutical ingredients (APIs) for ibogaine and psilocybin to pharmaceutical and biotechnology partners, enabling collaboration on next-generation mental health therapeutics. The lead program centers on a fixed-dose combination strategy, integrating a micro-dose of ibogaine with a validated SSRI, with ongoing exploration of safety, efficacy, and scalable manufacturing to support potential clinical use. Founding year and headquarters: PsyRx is led by an experienced management team with deep roots in the biotech and medical device sectors, and is headquartered in Israel, with a global focus on partnering and collaboration in pharmaceutical development. Core operations span research and development in CNS therapeutics, preclinical safety studies, and support for strategic partnerships and licensing of its psychedelic-assisted drug platform. The company positions itself as a seeker of rapid clinical benefits through combination regimens that aim to shorten time to therapeutic onset and improve adherence, while addressing limitations of current antidepressant treatments. Latest major company changes: PsyRx publicly reports progress through collaborations and program updates, including advancement of its toxicological safety studies for the SSRI–ibogaine combination, expansion of its clinical and regulatory planning for CNS indications, and ongoing engagement with potential industry partners to commercialize its drug development platform. The company also communicates milestones related to compound supply, such as GMP API availability for ibogaine and related psychoactive compounds, and has highlighted strategic shifts toward broader partnership models, including licensing and co-development arrangements to accelerate clinical progression and market access. PsyRx continues to refine its business model around combination therapies that leverage existing antidepressants with low-dose active compounds to improve outcomes and reduce treatment burden. Industry and business context: PsyRx operates within the CNS therapeutics and psychedelic-assisted drug development space, targeting major depressive disorder and related mood disorders. Its activities span target validation, lead discovery, lead optimization, and IND-enabling studies within a framework that emphasizes safety, tolerability, and patient lifestyle compatibility. The company focuses on partnerships with pharmaceutical and biotech entities, aiming to leverage external expertise and resources for clinical development, manufacturing, and commercialization. Substantial emphasis lies on creating first-in-class or best-in-class options through carefully calibrated, low-dose combination regimens that can be integrated with standard antidepressant therapy.